Procter & Gamble Health Q4 FY18 earnings call: Revenue & Margins
Q4 FY18 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #75 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Procter & Gamble Health Ltd's Q4 FY18 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
The investor presentation reports the following quarterly financial figures and changes: - EBITDA: INR 23.5 million, up 13% year-on-year.
From Procter & Gamble Health Ltd's Q4 FY18 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
2 more points from Procter & Gamble Health Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Procter & Gamble Health Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹382 Cr, net profit ₹112 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P & G Health Ltd's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q4 FY18 results?
The investor presentation reports the following quarterly financial figures and changes: - EBITDA: INR 23.5 million, up 13% year-on-year.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
